CTOs on the Move

Kronos Bio

www.kronosbio.com

 
Kronos Bio is clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription. Our proprietary product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks (TRNs) through which they drive oncogenic activity.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.kronosbio.com
  • 1300 So. El Camino Real Suite 300
    San Mateo, CA USA 94402
  • Phone: n/a

Executives

Name Title Contact Details

Funding

Kronos Bio raised $18M on 05/23/2018
Kronos Bio raised $155M on 08/25/2020

Similar Companies

deCODE genetics

deCODE genetics is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

The Coding Source LLC

The Coding Source LLC is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Ymmunobio

At Ymmunobio, our research is based on our deep understanding of immuno-oncology and precision cancer treatments. We leverage our profound knowledge of biologics, focusing on unique and first-in-class targets while selecting the optimal approach to dev...

Prosetta

Prosetta Biosciences, Inc. is an 11-year old biotechnology company developing novel small-molecule antiviral therapeutics based on over 25 years of basic research on the Cell-Free Protein Synthesizing Systems (CFPSS) by scientists at the University of California, San Francisco and the University of Washington, Seattle. The incorporation of the CFPSS in our drug discovery platform, has lead to the identification of small molecules which disrupt or alter the key protein-protein interactions involved with the assembly of viral capsids (the protein shell that protects the DNA or RNA genome of a virus). Prosetta has successfully produced highly potent compounds which display activity against multiple strains of many viral families including lead series of molecules that are effective antiviral agents against Influenza, HIV and HCV.

GrayBug

GrayBug® is a platform drug delivery company that is developing proprietary controlled release technologies for ophthalmic pharmaceutical indications. The company`s lead product is a polymer-drug biomolecular conjugate for the treatment of neovascular diseases, including age-related macular degeneration (AMD). GrayBug also has a proprietary platform technology that allows sustained drug delivery into various compartments of the eye while minimizing inflammation common with current controlled release technologies applied to the eye.